Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution ...

Novo Nordisk will launch its oral Ozempic pill for type 2 diabetes in the U.S. next week, offering competitive pricing and broad pharmacy availability. The move comes as rival Eli Lilly gains momentum ...

Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer ...

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO ...

Health Canada approved on Tuesday the first generic version of Danish drugmaker Novo Nordisk's Ozempic drug.

Novo Nordisk (NVO) stock is in focus as the company launches oral semaglutide as Ozempic pill for patients with type 2 ...

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an ...

Novo Nordisk CEO Mike Doustdar sits down with CNN to discusses manufacturing Wegovy pill in the U.S, direct to consumer ...

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO ...

Novo Nordisk says an oral semaglutide may help children and teens with Type 2 diabetes, with experts weighing benefits and ...

Novo Nordisk, which makes the GLP-1 semaglutide medications Ozempic and Wegovy, announced that it’s rolling out an “Ozempic ...

The drugmaker is getting on the AI train in ways that could move the needle down the road.